Literature DB >> 35154325

The Validation of a Simple, Robust, Stability-Indicating RP-HPLC Method for the Simultaneous Detection of Lamivudine, Tenofovir Disoproxil Fumarate, and Dolutegravir Sodium in Bulk Material and Pharmaceutical Formulations.

Omobolanle Ayoyinka Omoteso1, Marnus Milne2, Marique Aucamp1.   

Abstract

An effective analytical method is requisite to ensure the accurate identification and quantification of drug(s), either in bulk material or in complex matrices, which form part of finished pharmaceutical products. For the purpose of a pharmaceutical formulation study, it became necessary to have a simple, yet robust and reproducible reversed-phase HPLC method for the simultaneous detection and quantification of lamivudine (3TC), tenofovir disoproxil fumarate (TDF), and dolutegravir sodium (DTG) in bulk form, complex polymeric matrices, and during drug release studies. A suitable method was developed using a Kinetex® C18, 250 × 4.6 mm column as stationary phase and a mobile phase consisting of 50 : 50 v/v methanol and water with 1 mL orthophosphoric acid, with a flow rate of 1.0 mL/min and column temperature maintained at 35°C. A detection wavelength of 260 nm and an injection volume of 10 μL were used. The method was validated according to the International Conference on Harmonization (ICH) guideline Q2 (R1), and the parameters of linearity and range, accuracy, precision, specificity, limit of detection (LOD), limit of quantification (LOQ), robustness, and stability were all determined. Acceptable correlation coefficients for linearity (R2) of >0.998 for each of the three drugs were obtained. The LOD was quantified to be 56.31 μg/mL, 40.27 μg/mL, and 7.00 μg/mL for 3TC, TDF, and DTG, respectively, and the LOQ was quantified as 187.69 μg/mL, 134.22 μg/mL, and 22.5 μg/mL for 3TC, TDF, and DTG, respectively. In relation to all the determined validation parameters, this method proves to be suitable for the accurate identification and quantification of the three ARVs, either alone or in combination, as well as when incorporated into polymeric matrices. Furthermore, the method proves to be suitable to detect degradation of the compounds.
Copyright © 2022 Omobolanle Ayoyinka Omoteso et al.

Entities:  

Year:  2022        PMID: 35154325      PMCID: PMC8837449          DOI: 10.1155/2022/3510277

Source DB:  PubMed          Journal:  Int J Anal Chem        ISSN: 1687-8760            Impact factor:   1.885


  8 in total

1.  In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.

Authors:  Masanori Kobayashi; Tomokazu Yoshinaga; Takahiro Seki; Chiaki Wakasa-Morimoto; Kevin W Brown; Robert Ferris; Scott A Foster; Richard J Hazen; Shigeru Miki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

Review 2.  S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges.

Authors:  Johannes Carl Christoph Lenz; Jürgen Kurt Rockstroh
Journal:  Expert Opin Investig Drugs       Date:  2011-03-08       Impact factor: 6.206

3.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

Authors:  D J Hazuda; P Felock; M Witmer; A Wolfe; K Stillmock; J A Grobler; A Espeseth; L Gabryelski; W Schleif; C Blau; M D Miller
Journal:  Science       Date:  2000-01-28       Impact factor: 47.728

Review 4.  Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.

Authors:  Mackenzie L Cottrell; Tanja Hadzic; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

5.  Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA.

Authors:  B L Robbins; R V Srinivas; C Kim; N Bischofberger; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog.

Authors:  H Soudeyns; X I Yao; Q Gao; B Belleau; J L Kraus; N Nguyen-Ba; B Spira; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

7.  (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.

Authors:  J A Coates; N Cammack; H J Jenkinson; A J Jowett; M I Jowett; B A Pearson; C R Penn; P L Rouse; K C Viner; J M Cameron
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

8.  Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.

Authors:  Kathleen Squires; Anton L Pozniak; Gerald Pierone; Corklin R Steinhart; Daniel Berger; Nicholaos C Bellos; Stephen L Becker; Michael Wulfsohn; Michael D Miller; John J Toole; Dion F Coakley; Andrew Cheng
Journal:  Ann Intern Med       Date:  2003-09-02       Impact factor: 25.391

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.